Our current work is the first attempt to evaluate the role of CD133 expression in tumor cells for the prognosis of non-mucin producing ICC, providing additional insights on the molecular events responsible for prognosis prediction and antitumor potency. This evidence concerns the gene MUC5AC and neoplasm.